| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.11 | 0.02 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | -0.079 | 0.09 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.075 | 0.1 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | -0.059 | 0.2 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | -0.057 | 0.2 |
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | -0.055 | 0.2 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | 0.052 | 0.3 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.05 | 0.3 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.049 | 0.3 |
| mRNA | L-685458 | CCLE | pan-cancer | AAC | -0.042 | 0.3 |